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Several treatments have been attempted in amyotrophic lateral sclerosis (ALS)
animal models and patients. Recently, transplantation of bone marrow-derived
mononuclear cells (MNCs) was investigated as a regenerative therapy for ALS,
but satisfactory treatments remain to be established. To develop an effective
treatment, we focused onmesenchymal stem cells (MSCs) expressing hepatocyte
growth factor, glial cell line-derived neurotrophic factor, and insulin-like growth
factor using human artificial chromosome vector (HAC-MSCs). Here, we demon-
strated the transplantation of MNCs with HAC-MSCs in ALS mice. As per our re-
sults, the progression of motor dysfunction was significantly delayed, and their
survival was prolonged dramatically. Additional analysis revealed preservation
of motor neurons, suppression of gliosis, engraftment of numerous MNCs, and
elevated chemotaxis-related cytokines in the spinal cord of treated mice. There-
fore, growth factor-expressing MSCs enhance the therapeutic effects of bone
marrow-derived MNCs for ALS and have a high potential as a novel cell therapy
for patients with ALS.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that results in muscle weak-
ness caused by the loss of functioning of upper and lower motor neurons (Mitchell and Borasio, 2007; Rob-
berecht and Philips, 2013). Most patients with ALS are sporadic, but approximately 10% of the patients with
ALS have the disease traits in their genetic background (Pasinelli and Brown, 2006). Mutations in the super-
oxide dismutase (SOD) 1 gene is one of the most frequent causes of familial ALS in Asians, although the
GGGGCC (G4C2) repeat expansion in C9orf72 is the most commonly found mutation in Caucasians
(McCauley and Baloh, 2019; Rosen et al., 1993; Zou et al., 2017). Transgenic mice models that show an
overly high expression of the mutant SOD1 protein result in induced neuronal cell death in the central ner-
vous system and have been used as the representative animal models of ALS in a variety of experiments
(Gurney et al., 1994). The hSOD1G93A transgenic (SOD1-tg) mouse is themost commonly used ALSmouse
model (Gurney et al., 1994; Tu et al., 1996). Many researchers have used this mouse model and reported
pathological findings in the spinal cord and brain of mice (Magrané et al., 2012; Tu et al., 1996). There is
no established treatment for ALS, and many studies continue to conduct research to develop a cure (Abati
et al., 2019a; Baloh et al., 2018).
Stem cell therapy or regenerative therapy is an attractive strategy to provide great hope for the treatment
of an incurable disease like ALS (Abati et al., 2019b; Chen et al., 2016; Goutman et al., 2018). In regenerative
therapy, transplantation not only replaces damaged neurons but may also reverse their functioning by pro-
tecting weakened neurons and modulating the surrounding niche via the secretion of neurotrophic factors
(Kim et al., 2014; Krakora et al., 2013; Tang, 2017). As a regenerative therapy for ALS in mice models, we
previously have performed transplantation therapy of stem cell factor-modified bone marrow-derived
mononuclear cells (MNCs) and have reported their therapeutic effects in ALS mice (Terashima et al.,
2014). Our results showed that bone marrow-derived cells migrated into the spinal cord of ALS mice
and their neuroprotective effects were also observed (Terashima et al., 2014). However, the effects wereiScience 23, 101764, November 20, 2020 ª 2020 The Author(s).





Articlepartial and we postulated that additional modulation of the spinal cord niche would be required for the
successful engraftment of the transplanted cells.
As an alternative strategy for the treatment of ALS in mice models, we previously generated trophic factor-
expressing mesenchymal stem cells (MSCs)using human artificial chromosome vectors (Watanabe et al.,
2015). Artificial chromosome vectors have been developed and applied to novel therapeutic strategies
for cell-based therapies (Kouprina et al., 2014; Ikeno et al., 2020; Sinenko et al., 2020; Suzuki et al.,
2020). One of them, the 21st human chromosome vector (21HAC) has been engineered previously based
on truncation of human chromosome 21 by Oshimura lab for gene therapeutic applications (Katoh et al.,
2004). As a gene therapy vector, this 21HAC featured sustained gene expression, ability to insert large
genomic loci, and efficient insertion of multiple genes, and lack of insertional mutagenesis. Based on
the 21HAC vector (hereafter termed as HAC), we developed a gene therapeutic vector expressing three
growth factors: hepatocyte growth factor (HGF), glial cell line-derived neurotrophic factor (GDNF), and in-
sulin-like growth factor (IGF) (Watanabe et al., 2015). The cell lines established using HAC technology have
been named HAC-MSCs and have been used for studies on ALS treatment in experimental mice models
(Watanabe et al., 2015; Nakanishi et al., 2019). We focused on HAC-MSCs expressing the three growth fac-
tors, which have been reported to have effects on ALS rodents (Dodge et al., 2008; Kaspar et al., 2003; Sun
et al., 2002; Wang et al., 2002), because HAC-MSCs are expected to improve the environment and the niche
surrounding neurons in the spinal cord of ALS. This might provide successful engraftment of bone marrow-
derived MNCs in ALS mouse model.
Therefore, in the present study, we have demonstrated a new transplantation therapy of bone marrow-
derivedMNCs with HAC-MSCs expressing growth factors for the ALS mouse model with an aim to increase
the therapeutic effects of the transplanted cells. We have also analyzed the engraftment of transplanted
cells in ALS mice. Additionally, we successfully demonstrated the efficacy of the combination transplanta-
tion therapy.RESULTS
Preparation of MNCs and HAC-MSCs and Experimental Design for the Treatment of SOD1-tg
For bonemarrow transplantation therapy in SOD1-tgmice, MSCs expressing HGF, GDNF, and IGF by HAC
(HAC-MSCs, Figures S1 and 1), MSCs containing the control HACwithout growth factor expression but with
green fluorescent protein (GFP) (GFP-MSCs, Figures S1 and 1), and MNCs were prepared (Figure 1). GFP-
MSCs and HAC-MSCs were confirmed to express GFP under a microscope (Figure 1A). In contrast, MNCs,
which were isolated from bone marrow of tdTomato red fluorescent protein (hereafter tdTomato)-express-
ing transgenic mice, were distinguished from the HAC-MSCs population by differences in expressing-fluo-
rescent protein (Figure 1A). HAC-MSCs expressed significantly higher levels of the three growth factors as
compared with GFP-MNCs as shown in the HGF, GDNF, and IGF enzyme-linked immunosorbent assay
(ELISA) analysis, whereas MNCs did not show any expression (Figure 1B). These cells were then used for
cell therapy in SOD1-tg mice. Eight-week-old female SOD1-tg mice were transplanted as follows: only
MNCs (MNCs group), MNCs with control MSCs (MNCs + GFP-MSCs group), or MNCs with HAC-MSCs
(MNCs + HAC-MSCs group) (Figure S2). The transplanted mice were monitored for their body weight,
neurological behavior, and survival rate to evaluate the therapeutic effects of the transplanted cells and
also analyzed for their histological and biological features (Figure S2).Effects of Combined Bone Marrow Transplantation Therapy in SOD1-tg Mice
Eight-week-old female SOD1-tg mice underwent cell therapy after initial examination for motor behavior
using the Rota-Rod test and full body irradiation. Bodyweight, motor function, and survival rates were
investigated every week until the Rota-Rod test was zero seconds, and the results were compared with
those of the non-transplanted SOD1-tg mice (SOD1-tg group) (Figure 2). Body weight of the SOD1-tg
group was heavier than that of the three treatment groups at some time points, but there was no significant
difference among the three cell therapy groups throughout the monitoring period except at 20 W (Fig-
ure 2A). Only at 20 W, body weight in the MNCs + HAC-MSCs group was significantly heavier than that
in the other two cell therapy groups (Figure 2A). Next, three bone marrow transplantation groups showed
a trend toward improved motor behavior compared with the no-treatment SOD1-tg mice (Figure 2B). In
particular, the therapeutic effects were considerably enhanced in the MNCs + HAC-MSCs group as
compared with all other groups at 18–22W (Figure 2B). For the survival rate, the MNCs + HAC-MSCs group2 iScience 23, 101764, November 20, 2020
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Figure 1. Characterization of MNCs, GFP-MSCs, and HAC-MSCs
(A) Images of primary MNCs from tdTomato transgenic mice and cultured GFP-MSCs and HAC-MSCs. Scale bar, 20 mm.
(B) ELISA analysis of HGF, GDNF, and IGF in the media of MNCs (n = 8), GFP-MSCs (n = 8), and HAC-MSCs (n = 8) after
3 days of culture. **p < 0.01 between HAC-MSCs and the others. Error bars represent themean + SD. GDNF, glial cell line-
derived neurotrophic factor; GFP, green fluorescent protein; HAC, human artificial chromosome vectors; HGF, hepatic




Articleshowed the most effective results among all the groups, similar to that of the motor function test
(Figure 2C).
Histological Analysis of the Spinal Cord and Muscle in SOD1-tg Mice after Cell Therapy
To evaluate the effects of cell therapy, Nissl staining was performed to observe motor neuron survival in the
spinal cord at middle (14–16 W) and end stages (18–20 W) of disease after cell therapy (Figure 3). At the
middle stage of the disease, Nissl-positive staining was the same level among the three treatment groups
and SOD1-tg disease control group (Figure 3A upper 2 rows and 3B left side). These results suggested that
the motor neurons were still preserved in the SOD1-tg group compared with the other three cell therapy
groups. However, Nissl staining was decreased at the end stage of disease in the SOD1-tg group (Figure 3A
lower 2 rows and 3B right side). In contrast, MNCs, MNCs + GFP-MSCs, and MNCs + HAC-MSCs groups
showed significantly higher intensity of Nissl staining when compared with the SOD1-tg group. In addition,
the MNCs + HAC-MSCs group showed the highest staining intensity among all the four groups (Figures 3A
and 3B). As another finding, a few MNCs were observed to be attached to neurons in the MNCs + HAC-
MSCs group (Figure 3A arrowheads). These results suggest that neurons were somehow influenced by
MNCs and that neuronal loss from middle to end stage of the disease was suppressed in the MNCs +
HAC-MSCs group. Next, gliosis in the spinal cord of SOD1-tg mice was evaluated after cell therapy using
GFAP immunostaining (Figure 4A). GFAP staining in the three cell therapy groups was significantly weaker
than that in the SOD1-tg group at the end stage of the disease (Figure 4B). The MNCs + HAC-MSCs group
showed the weakest staining in the four groups. These results were similar to those of Nissl staining, but
GFAP staining in MNCs + GFP-MSCs was weaker than that in MNCs (Figures 4A and 4B). These results indi-
cate that the MNCs + HAC-MSCs therapy group was most effective for the suppression of gliosis and that
the MSCs likely contributed to the neuroprotective effect compared with MNCs. Muscle degeneration was
also evaluated by measuring the muscle fiber area in the anterior tibial muscle of SOD1-tg mice after cell
therapy (Figures 4C and 4D). The muscle fiber area was preserved in the three cell therapy groups and was




Figure 2. Bone Marrow Transplantation Effects on Bodyweight, Motor Function, and Survival in SOD1-tg
(A) Bodyweight (BW) was measured once a week in the SOD1-tg mice without treatment (n = 15) or with MNCs (n = 15),
MNCs + GFP-MSCs (n = 16), or MNCs + HAC-MSCs transplantation (n = 18). *p < 0.05 between the SOD1-tg group and
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the others. #p < 0.05 between the MNCs + HAC-MSCs group and the other two treatment groups. The error bars
represent the mean G SD.
(B) Rota-rod test was performed in same four groups. *p < 0.05 between MNCs + HAC-MSCs group and others at each
time point. The error bars represent the mean G SD.
(C) Survival curves were analyzed in same four groups. *p < 0.05 between the MNCs + HAC-MSCs group and the others




Articlegroups for the suppression of gliosis andmuscle degeneration were shown only at the end stage and not at
the middle stage, similar to the effect observed on motor neurons (data not shown).
Histological Analysis of Transplanted Cells in the Spinal Cord and Bone Marrow Tissues of
SOD1-tg Mice
Next, to analyze the mechanism by which the MNCs + HAC-MSCs group showed an increase in the ther-
apeutic effects observed above, histological experiments were performed on spinal cord and bonemarrow
tissues of 16-week-old SOD1-tg mice in three therapeutic groups. Sections of the spinal cord and bone
marrow were prepared and observed for GFP (green) and tdTomato (red) fluorescent signals under a fluo-
rescence microscope (Figure S3). In the spinal cord sections, GFP signals were observed occasionally in
MNCs + GFP-MSCs and MNCs + HAC-MSCs groups (Figure S3A). However, an increased number of
red signals were observed in the spinal cord sections of MNCs + HAC-MSCs group when compared
with the other two groups (Figure S3A). These results showed that many MNCs have migrated into the spi-
nal cord of the SOD1-tg mice transplanted with MNCs + HAC-MSCs. In bone marrow tissues, many GFP-
positive cells were observed in MNCs + GFP-MSCs and in MNCs + HAC-MSCs groups, whereas the tdTo-
mato-positive MNCs were diffusely present in all groups (Figure S3B). These results suggest that each pop-
ulation of transplanted cells colonized the bone marrow of the recipient SOD1-tg mice.
In addition, we compared the population of tdTomato-positive MNCs among the three kinds of bone
marrow transplantations because tdTomato-positive cells in the MNCs + HAC-MSCs group migrated in
large numbers to the spinal cord. Spinal cord sections were obtained from MNCs, MNCs + GFP-MSCs,
and MNCs + HAC-MSCs groups and seen for the presence of red fluorescence (Figure 5). In all three
groups, tdTomato-positive MNCs were diffusely observed in 14- to 16-week-old SOD1-tg mice after trans-
plantation (Figure 5A). However, the number of MNCs (red fluorescent-positive cells) increasedmarkedly in
only the MNCs + HAC-MSCs group (Figures 5A and 5B). The number of tdTomato positive cells were
approximately three times higher in the MNCs + HAC-MSCs group than in the MNCs and MNCs + GFP-
MSCs groups (Figure 5B).
Furthermore, we also performed counter-staining of themigratedMNCs to clarify their characteristics. Sec-
tions were prepared from spinal cords of 16-week-old SOD1-tg mice after transplantation of MNCs + HAC-
MSCs. Histological analysis of the sections was performed using b-tubulin immunostaining as a neuronal
marker, glial fibrillary acidic protein (GFAP) as an astrocyte marker, and ionized calcium-binding adapter
molecule 1 (Iba1) as a microglia marker (Figure 5C). Red fluorescent signals for tdTomato protein were
diffused in the spinal cord, and over half of the signals co-localized with Iba1 staining pattern but not
with b-tubulin and GFAP staining (Figure 5C). These results suggest that a large number of MNCs that
have migrated to the spinal cord showed microglia-like features but did not seem to differentiate into
neurons.
Expression of Growth Factors and Reporter Genes in the Transplanted SOD1-tg Mice
Spinal cord tissues were obtained from 16- to 18-week-old SOD1-tg mice after transplantation of the three cell
therapy groups. Quantitative PCR of HGF, GDNF, and IGF was performed in spinal cord tissues of no treatment,
MNCs, MNCs + GFP-MSCs, and MNCs + HAC-MSCs groups (Figures 6A–6C). Significant mRNA expression of
human HGF, GDNF, and IGF genes was recognized only in the MNCs + HAC-MSCs group (Figures 6A–6C).
These results suggest that the transgenes fromHAC-MSCswere specifically expressedat the pathological lesion
sites of the spinal cords. Additionally, the tdTomato and GFP genes in the spinal cord of SOD1-tg mice were
quantitated by PCR after each transplantation (Figures 6D and 6E). tdTomato gene expression was much higher
in the MNCs + HAC-MSCs group than in the MNCs and MNCs + GFP-MSCs groups (Figure 6D). These results
were consistentwith the histological analysis of tdTomato-positiveMNCs (Figures 5A and 5B). GFPgeneexpres-
sion, which originated from MSCs, was recognized in only the MNCs + GFP-MSCs and MNCs + HAC-MSCs
groups (Figure 6E). The expression level of GFP was significantly higher in the MNCs + HAC-MSCs groupiScience 23, 101764, November 20, 2020 5
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Figure 3. Histological Analysis of Motor Neurons in the Spinal Cord in SOD1-tg After Cell Transplantation
Therapy
(A) Nissl stain (blue) with GFP (GFP-MSCs or HAC-MSCs; green) and tdTomato (MNCs; red) signals in anterior horns of the
spinal cords in the SOD1-tg, MNCs, MNCs + GFP-MSCs, andMNCs + HAC-MSCs groups at the middle stage (Mid: 14–16
W) and the end stage (End: 18–20 W) of the disease. Upper row in each stage shows the color images and lower row in
each stage shows black and white images of blue color (Nissl staining) isolated from the corresponding upper row. The
arrowheads show the MNCs attached to the Nissl positive neurons. Scale bar, 100 mm.
(B) Relative intensity of Nissl staining as seen in the SOD1-tg, MNCs, MNCs +GFP-MSCs, andMNCs + HAC-MSCs groups
at the middle stage (Mid: 14–16 W) (n = 5 in each group) and the end stage (End: 18–20 W) (n = 5 at each group) of the
disease. The intensity of Nissl staining was measured in the black and white image in (A) using the ImageJ software and
the ratio was calculated against the intensity of that in SOD1-tg at end stage. *p < 0.05. **p < 0.01. n.s.: not significant. The
error bars represent the mean + SD.
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Figure 4. Histological Analysis of Gliosis in Spinal Cord and Muscle Degeneration in SOD1-tg After Cell Transplantation Therapy
(A) GFAP immunohistochemistry (blue) with GFP (GFP-MSCs or HAC-MSCs; green) and tdTomato (MNCs; red) signals in anterior horns of the spinal cords in
SOD1-tg, MNCs, MNCs + GFP-MSCs, andMNCs + HAC-MSCs groups at 18–20 weeks old. Upper row in each stage shows the color images and lower row in
each stage shows black and white images of blue color (GFAP staining) isolated from the corresponding upper row. Scale bar, 100 mm.
(B) The bar graph shows relative intensity of GFAP positive staining in same four groups at the 18–20 weeks old (n = 5 at each group). The intensity of GFAP
staining was measured in the black and white image as shown in lower picture of left side by ImageJ software and the ratio was calculated against the
intensity of that in SOD1-tg. *p < 0.05. **p < 0.01. Scale bar, 100 mm. Error bars represent the mean + SD.
(C) Hematoxylin-eosin stain of anterior tibial muscle in SOD1-tg, MNCs, MNCs + GFP-MSCs and MNCs + HAC-MSCs groups and wild-type mice at 18–
20 weeks old. Scale bar, 100 mm.
(D) Bar graph indicates the area of each muscle fiber in five groups. The average areas of muscle fibers were compared among the four disease groups (n = 5




Articlethan in the MNCs + GFP-MSCs group (Figure 6E). These results suggest that the transplanted MSCs have to a
higher degree migrated and colonized the spinal cords in the MNCs + HAC-MSCs group than in the MNCs +
GFP-MSCs group. Next, ELISA of HGF, GDNF, and IGF was performed to evaluate the protein expression level
in spinal cord tissues from14 to 16W (middle stage) and 18–20W (end stage) SOD1-tgmice after transplantation
therapy (Figures 6F–6H). Expression levels of HGF, GDNF, and IGF were observed at a significantly high level iniScience 23, 101764, November 20, 2020 7
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Figure 5. Accumulation and Characteristic Analysis of MNCs in the Spinal Cord of the SOD1-tg Mice After Cell Transplantation Therapy
(A) tdTomato (MNCs; red and left side) signals with a nuclear stain (DAPI, blue, middle, and right side) in the sections of whole spinal cords of 14 to 16-week-
old SOD1-tg mice from the MNCs, MNCs + GFP-MSCs, and MNCs + HAC-MSCs transplantation groups. Scale bars, 100 mm.
(B) The number of MNCs in spinal cord sections of 14- to 16-week-old SOD1-tg mice after transplantation of MNCs (n = 5), MNCs + GFP-MSCs (n = 5), and
MNCs + HAC-MSCs (n = 5) groups. *p < 0.05 between the MNCs + HAC-MSCs group and the others. The error bars represent the mean + SD.
(C) Counterstain of spinal cord sections of 14- to 16-week-old SOD1-tg mice from the MNCs + HAC-MSCs group was performed for b-tubulin in neuron (left
side lane), for GFAP in astrocyte (middle lane), and for Iba1 in microglia (right side lane). HAC-MSCs shows GFP protein (green) and MNCs shows tdTomato
protein (red). The staining of b-tubulin, GFAP, and Iba1 are shown in blue color. Arrows indicate endogenous b-tubulin-positive neurons, GFAP-positive




Articlethe spinal cord of MNCs + HAC-MSCs group at both the middle and end stages, whereas the SOD1-tg group
and the other two groups hardly expressed any of the three proteins in both stages. However, the expression
levels of the three proteins were not different between the two stages in theMNCs+HAC-MSCs group (Figures
6F–6H).
Expression of Cytokines in the Spinal Cords of SOD1-tg Mice
Spinal cord tissues were collected from 16- to 18-week-old SOD1-tg mice after MNCs, MNCs +GFP-MSCs,
and MNCs + HAC-MSCs transplantation procedure was carried out. The concentrations of 32 cytokines
were measured in the spinal cord tissues of the three groups (Figure 7). Cytokine expression was repre-
sented on a red-blue color scale against the expression level of no-treatment SOD1-tg mice (Figure 7A).
The expression of only five cytokines, granulocyte-colony-stimulating factor (G-CSF), interleukin (IL)-9,
macrophage inflammatory protein (MIP)-1a, monokine induced by interferon-g (MIG), and vascular endo-
thelial growth factor (VEGF), increased gradually from the MNCs group to the MNCs + GFP-MSCs groups
and from MNCs + GFP-MSCs to MNCs + HAC-MSCs groups (Figure 7A, yellow highlight). The above-
mentioned five cytokines were elevated by the addition of MSCs and further elevated by the expression
of three growth factors by HAC-MSCs (Figure 7B). The concentration of IL-9 in the spinal cord of the
MNCs + HAC-MSCs group was four times higher than that in the no-treatment SOD1-tg mice, which
showed the highest rate among the five cytokines (Figure 7B). The concentrations of the other four cyto-
kines were approximately two times higher than those in the no-treatment SOD1-tg mice (Figure 7B).
Conversely, IL-1b decreased in the MNCs + HAC-MSCs group when compared with no-treatment
SOD1-tg mice. However, the level of reduction was smaller than in the MNCs group (Figure 7A). These re-
sults did not seem to reflect the additional effects of HAC-MSCs into the MNCs group.
DISCUSSION
Primary bone marrow MNCs are a heterogeneous population that includes hematopoietic lineage cells
such as lymphocytes, monocytes, hematopoietic stem cells, and progenitor cells. MSCs are multipotent
cells that can differentiate into osteoblasts, chondrocytes, myocytes, and adipocytes and are known to pro-
vide a supportive microenvironmental niche for hematopoietic stem cells. In this study, we used immortal-
ized MSCs, which were originally derived from the bone marrow. We used a combination of MNCs and
MSCs because immortalized MSCs would support the survival of primary MNCs and the secreted neuro-
trophic factors would further strengthen the trophic effect of MSCs.
This study showed that a combined bone marrow transplantation (BMT) of MNCs and growth factor-ex-
pressing MSCs (HAC-MSCs) enhanced the effect of BMT therapy of MNCs on ALS disease progression
and survival in mice models. After MNCs + HAC-MSCs therapy, the number of bone marrow-derived
MNCs that homed to the spinal cord in SOD1-tg mice increased markedly, as detected by the expression
of the tdTomato protein. This phenomenon was remarkably the most different in MNCs + HAC-MSCs ther-
apy compared with that in MNCs and MNCs + GFP-MSCs transplantation groups, which could be related
to the expression of cytokines in the spinal cord and their therapeutic effects in SOD1-tg mice.
Previous reports have shown that BMT preserved motor function and prolonged the survival time of SOD1-
tgmice (Ohta et al., 2011; Silani et al., 2004; Venturin et al., 2016). BMT has been experimentally used for the
treatment of patients with ALS in conjunction with total body irradiation (Appel et al., 2008). Similarly, we
have also reported the therapeutic effects of stem cell factor-modified bone marrow transplantation in
SOD1-tg mice (Terashima et al., 2014). In this study, the transplanted cells did not differentiate into neu-
rons. Instead, the neuroprotective effects of the transplant were observed because the expression of in-
flammatory cytokines was suppressed, which improved the pathological conditions in the spinal cord of
SOD1-tg mice via microglia-like cells of donor origin (Ohta et al., 2011; Terashima et al., 2014; VenturiniScience 23, 101764, November 20, 2020 9
Figure 6. Analysis of mRNA and Protein Levels in the Spinal Cord of SOD1-tg After Transplantation of HAC-MSCs
and MNCs
(A–C) mRNA expression level of growth factors including HGF (A), GDNF (B), and IGF (C) in the spinal cord of 16- to 18-
week-old SOD1-tg mice were analyzed and compared among the control SOD1-tg (n = 5), MNCs (n = 5), MNCs + GFP-
MSCs (n = 5), andMNCs + HAC-MSCs (n = 5) groups. The y axis shows mRNA expression standardized with b-actin mRNA
expression. **p < 0.01 between the MNCs + HAC-MSCs group and the others. Error bars represent the mean + SD.
(D and E) mRNA expression level of tdTomato (D) andGFP gene (E) was observed in control SOD1-tg (n = 5), MNCs (n = 5),
MNCs + GFP-MSCs (n = 5), and MNCs + HAC-MSCs (n = 5) groups. *p < 0.05 between MNCs + HAC-MSCs group and
others. Error bars represent the mean + SD.
(F–H) ELISA analysis of growth factors including HGF (F), GDNF (G), and IGF (H) in spinal cord at SOD1-tg, MNCs, MNCs +
GFP-MSCs, andMNCs + HAC-MSCs groups at middle stage (Mid: 14–16W) (n = 5 at each group) and end stage (End: 18–





Articleet al., 2016). In the current study, migration of a large number of transplanted MNCs was observed in the
spinal cord, and some of them showed expression of microglial markers and were also likely attached to
neurons. This migration and expression could be the reason for the therapeutic effects that are observed
as is consistent with a previous report (Terashima et al., 2014).
In the current study, transplantation of MNCs + GFP-MSCs did not show enhanced effects on motor func-
tion and survival compared with the MNCs group; however, it demonstrated the therapeutic effects10 iScience 23, 101764, November 20, 2020
Figure 7. Quantitative Analysis of Cytokines in the Spinal Cord of SOD1-tg After Transplantation of HAC-MSCs
and MNCs
(A) The protein concentration of 32 cytokines was measured in the spinal cord combined from over three 16- to 18-week-
old SOD1-tg mice in the control SOD1-tg, MNCs, MNCs + GFP-MSCs, and MNCs + HAC-MSCs groups. The ratio of the
protein concentration of the cytokines in each group was compared against that of the control SOD1-tg to each MNCs,
MNCs + GFP-MSCs, and MNCs + HAC-MSCs groups. Red color indicates the upregulation of cytokines expression and
blue color indicates the downregulation against the SOD1-tg group. Yellow highlight indicates the cytokines with gradual
increase in expression levels from MNCs to MNCs + HAC-MSCs. Red bars indicate the elevated cytokine levels, and blue
bars indicate the decreased cytokines in the MNCs group when compared with the SOD1-tg group.
(B) After picking up five yellow-highlighted cytokines, their protein expression ratio was calculated against control SOD1-




Articlediscussed above when compared with the no-treatment group. MSCs have been widely researched for
their usage in regenerative therapies for neuronal diseases such as stroke and neurodegenerative diseases
(Tanna and Sachan, 2014). MSCs transplantation has been shown to be effective in the mice model of ALS,
and the mechanisms underlying the therapeutic effects of the transplantation appear to be highly depen-
dent on two major outcomes: motor neuron survival and an increase in regeneration of the diseased
neuronal tissues (Kim et al., 2010; Zhang et al., 2009). MSCs have already been used in clinical studies
for ALS treatment (Mazzini et al., 2010, 2012). In these studies, the MSCs were directly administered into
ALS mice and patients through intrathecal or local injection (Kim et al., 2010; Mazzini et al., 2010, 2012;
Zhang et al., 2009). We have also previously shown effective results with the intrathecal administration route
for injection of the cells (Watanabe et al., 2015). However, this study used BMT strategy through intravenous
injection, and this was different from the methods used in previous studies. Owing to the differences be-
tween these approaches, MNCs + GFP-MSCs may result in no enhanced effects on motor function and sur-
vival compared withMNCs.Moreover, a combination of humanMSCs and human chromosome vectors was




Articlebe widely used in future clinical settings. Therefore, histocompatibility-related issues could occur with re-
gard to xenogeneic human MCSs and allogeneic mouse MNCs, even though immunosuppressants were
used in this study. In mouse MSCs, HAC is less stable, possibly because of differences in centromeres be-
tween humans and mice. Therefore, we started to use human MSCs for HAC in the series of our experi-
ments; however, it was recently reported that a novel version of mouse artificial chromosome (MAC), a
mouse counterpart of HAC, is stably maintained in mouse cells (Shimohara et al., 2017). If a combination
of mouse MSCs and MAC is used, it may have yielded better results. Despite the probability of histocom-
patibility-related issues occurring in our experimental settings, the MNCs + HAC-MSCs transplant group
showed a remarkable therapeutic effect. As an evidence in support of the therapeutic effect, it is worth
noting that human HGF, GDNF, and IGF are shown to have biological activities in mice (Seishima et al.,
2019; Tamura et al., 1989; Zhang et al., 2018). Considering HAC-MSCs have overcome negative factors
such as histocompatibility-related problems against mouse and have shown therapeutic effect in this study,
we expect that the usage of HAC-MSCs could bring more therapeutic effects to patients with ALS with allo-
genic administration.
The effects of either MNCs or MSCs transplantation monotherapy are limited, and improvements are ex-
pected. In this study, we have shown the advantage of using a combined cell transplantation as the ther-
apeutic strategy as compared with monotherapy with just MNCs or MSCs. Reasons for this advantage can
be attributed to the expression of the growth factors including HGF, GDNF, and IGF, and it is this expres-
sion that majorly confers the overall therapeutic effects observed in this study. Supplementation of growth
factors has been classically attempted for a long time (Azzouz et al., 2004; Dodge et al., 2008; Kaspar et al.,
2003; Wang et al., 2002). HGF, GDNF, and IGF are the most widely used growth factors in ALS therapeutic
research, as some studies have shown their usage to be effective in mice models for ALS (Dodge et al.,
2008; Kaspar et al., 2003; Sun et al., 2002; Wang et al., 2002). Clinical trials have also been conducted for
the use of HGF, GDNF, and IGF in the ALS therapy in several countries (Sakowski et al., 2009; Sufit et al.,
2017). HGF is known to act on epithelial, endothelial, and hematopoietic cells and is related to organ devel-
opment and regeneration (Nakamura et al., 2011). In an ALS mouse model, HGF suppressed neuronal
apoptosis and degeneration (Sun et al., 2002). GDNF and IGF have also shown to suppress apoptosis of
motor neurons in ALS mice (Dodge et al., 2008; Kaspar et al., 2003; Wang et al., 2002). Additionally,
GDNF and IGF are shown to induce brain development and neurite extension similar to that induced by
the TGF family of growth factors (Connor and Dragunow, 1998). These factors exert their trophic effects
through common signaling pathways such as the AKT and ERK pathway by binding to their respective acti-
vating receptors: RET/GFRa for GDNF, C-MET for HGF, and IGF-1R for IGF-1. We used these three growth
factors simultaneously because the expression of each of these receptors, i.e., c-RET, C-MET, and IGF-1R, is
decreased in the spinal cord motor neurons in ALS (Kato et al., 2003; Ryu et al., 2011; Steyn et al., 2012).
Since there is a decrease in all the three receptor expression levels, we hypothesized that using just one
or two factors would be a weak strategy to obtain a considerable therapeutic effect. Hence, the higher ther-
apeutic effects of using all the three growth factors simultaneously as a treatment strategy in the SOD1-tg
mice was considered as an acceptable result by us, as we observed high levels of their expression in the
spinal cord of these mice.
Furthermore, five kinds of cytokines, namely, G-CSF, IL-9, MIP-1a, MIG, and VEGF, showed an increased
level of expression in the spinal cord of SOD1-tg after MNCs + HAC-MSCs transplantation. These results
could explain the increased number of bone marrow-derived MNCs that homed specifically to the spinal
cord in the SOD1-tg mice. G-CSF, IL-9, MIP-1a, and MIG are known to promote differentiation, multiplica-
tion, and chemotaxis of hematopoietic cells (Keller et al., 1994; Liao et al., 1995; Miller and Krangel, 1992;
Wang et al., 1999; Welte et al., 1985). Therefore, these cytokines might also be related to the migration of
MNCs in the HAC-MSCs transplant group. G-CSF has also been reported to directly suppress disease pro-
gression and improve survival rates in ALS mice models (Pitzer et al., 2008). VEGF is known to promote
angiogenesis and is regulated by HGF expression (Xin et al., 2001). Thus, the elevation of VEGF in this study
would have been caused due to the overexpression of HGF. VEGF expression has been shown to be
induced by hypoxia and oxidative stress (Shweiki et al., 1992). However, VEGF was not elevated under
oxidative conditions in an ALS mouse model (Moreau et al., 2006). ALS disease conditions progress faster
by the deletion of the hypoxia-response element in the VEGF promoter (Oosthuyse et al., 2001). Therefore,
a decrease in VEGF expression is intrinsically related to ALS progression, and supplementation with VEGF
has therapeutic potential for ALS. Thus, VEGF induced by HGFmay play a pivotal role in the amelioration of




ArticleThe theory of non-cell autonomous neuronal cell death is well known in the pathogenesis of neurodegen-
erative diseases (Ilieva et al., 2009; Tang, 2017). This theory states that immune cells, endothelial cells, and
astrocytes surrounding the neurons are also subjected to pathological changes in the course of the disease
(Ilieva et al., 2009; Tang, 2017). In our study, the expression of HGF, GDNF, and IGF was increased after the
transplantation of HAC-MSCs, but HAC-MSCs were not observed in large numbers in the spinal cord after
treatment. Instead, MNCsmigrated very well into the spinal cord only in theMNCs + HAC-MSCs transplant
group. Therefore, our results clearly indicate that MSCs provided no direct neuroprotective effect but
instead indirectly affected the spinal cord promoting chemotaxis of MNCs. This migration could have pro-
moted a change in the spinal cord niche leading to a minimized inflammatory and oxidative condition due
to the elevated expression levels of cytokines and growth factors.
Considering all the results together observed in the current study, we suggest a timeline wherein the
migration of MNCs and growth factor expression precede histological and behavioral effects of the com-
bination therapy of MNCs and HAC-MSCs transplantation. Therefore, the two events of MNCs migration
and growth factor expression could be the reasons to explain the remarkable therapeutic effect observed
during this combination therapy. We believe that improvement in the microenvironmental niche of the spi-
nal cord was inducedmajorly by the HAC-MSCs-derived cytokines promoting themigration of MNCs to the
spinal cord region. The expression of the three growth factors that are also from HAC-MSCs confer a direct
neuroprotective effect on the neuronal cells and the spinal cord tissue. Thus, we postulate that the simul-
taneous action of theMNCsmigration coupled with the expression of growth factors, all which occur driven
by the presence of HAC-MSCs, brought about the distinct and precise therapeutic effect in the ALS mouse
models.
Despite recent advances in stem cell therapies, ALS remains non-curable and clinical remission or reversal
remains to be achieved. Although bone marrow or MSCs transplantation has already been attempted in
ALS mice and patients, their efficacy has been limited (Appel et al., 2008; Kim et al., 2010; Mazzini et al.,
2010, 2012; Ohta et al., 2011; Silani et al., 2004; Venturin et al., 2016; Zhang et al., 2009). Therefore, to
improve the therapeutic effects, we demonstrated a new therapeutic approach that combines MNCs
and MSCs with the overexpression of growth factors such as HGF, GDNF, and IGF, whose efficacy has
been reported for ALS (Dodge et al., 2008; Kaspar et al., 2003; Sun et al., 2002; Wang et al., 2002). The re-
sults of our combined transplantation strategy have conferred a clear therapeutic advantage, compared
with the transplantation of either MNCs or MSCs, which can be attributed to the migration of a large num-
ber of MNCs to the spinal cord and also the elevation of several cytokine expression levels. We conclude
that growth factor-expressing mesenchymal stem cells improve the therapeutic effects of bone marrow-
derived mononuclear cells for ALS. Additionally, we suggest that this therapy may be a promising new
strategy for the treatment of ALS patients.Limitations of the Study
We developed a novel cell therapy for amyotrophic lateral sclerosis (ALS) using combined transplantation
of bone marrow-derived mononuclear cells (MNCs) and growth factor-expressing mesenchymal stem cells
(HAC-MSCs). The transplanted MNCs with the aid of MSCs expressing HGF, GDNF, and IGF significantly
improved their therapeutic efficacy for ALS. Although this novel cell therapy has a high therapeutic poten-
tial for the treatment of patients with ALS, it is necessary to further investigate the detailed mechanisms of
the effects brought about by this combined transplantation strategy, the safety of artificial chromosome
vectors, immortalized MSCs, and the risk of bone marrow transplantations in clinical applications. In partic-
ular, the possibility of tumorigenesis with artificial chromosome vectors and immortalized MSCs should be
studied in detail, and adaptation to this therapy should be considered carefully owing to the side effects of
whole-body irradiation used during bone marrow transplantations.Resource Availability
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Figure S1. Scheme for generating HAC-MSCs with growth factor-expression and GFP-MSCs, 
related to Figure 1.
Green fluorescent protein (GFP), hepatocyte growth factor (HGF), glial cell line-derived neurotrophic
factor (GDNF), insulin-like growth factor (IGF) genes and hygromycin resistance gene (hyg) were
cloned into 21st human artificial chromosome vector (HAC) (Katoh et al., 2004, Watanabe et al., 2015).
Immortalized human mesenchymal stem cells (MSCs) were prepared by insertion of human
telomerase reverse transcriptase (hTERT) and human papillomavirus (HPV)16 E6/E7 genes. After the
HAC was transferred into the immortalized MSCs by microcell mediated chromosome transfer
(MMCT), the line of growth factor-expressing human artificial chromosome-mesenchymal stem cells
(HAC-MSCs) was generated with hygromycin selection. As an experimental control cells, control
MSCs (GFP-MSCs) were generated by insertion of 21st human artificial chromosome vector including












Control HAC-mesenchymal stem cells 
(GFP-MSCs)
or
Figure S2. Schematic experimental design for transplantation of MNCs and HAC-MSCs with
growth factor-expression, related to Figure 2-7. Primary MNCs from tdTomato transgenic mice
and cultured HAC-MSCs were mixed and transplanted into irradiated 8-week-old female SOD1
G93A transgenic mice for the cell therapy of motor neuron diseases. Therapeutic effects were
compared to only MNCs and MNCs + GFP-MSCs transplantation groups. SOD1-tg mice after three
kinds of cell therapy were monitored body weight (BW), Rota-rod test and survival rate. In addition,
histological and biological analysis were performed at the time point of black bar in above time
course. ELISA; enzyme-linked immuno-sorbent assay, GDNF; glial cell line-derived neurotrophic
factor, GFP; green fluorescent protein, HGF; hepatic growth factor, IGF; insulin-like growth factor,


























Figure S3. Histological analysis of spinal cord and bone marrow in SOD1-tg after cell
therapy, related to Figure 5. (A) GFP (GFP-MSCs or HAC-MSCs; green), tdTomato (MNCs; red)
signals and nuclear stain (DAPI, blue) in the sections of spinal cords in MNCs, MNCs + GFP-MSCs
and MNCs + HAC-MSCs groups at 16 weeks old. Scale bar = 100 mm. (B) GFP (GFP-MSCs or
HAC-MSCs; green), tdTomato (MNCs; red) and nuclear stain (DAPI, blue) in the sections of bone




























C57BL/6 (WT), B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J and B6SJL-
Tg(SOD1*G93A)1Gur/J (SOD1-tg) mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME). Female SOD1-tg mice were used for the 
experimental study and male SOD1-tg mice were used only for the breeding. 
tdTomato-systemic expressing transgenic mice were generated by breeding 
B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J and Ayu1 promoter-driven Cre 
recombinase-expressing mice (Ayu1-Cre, Niwa et al., 1993), kindly gifted by 
Dr. Niwa. All animals were housed and provided with water and mouse chow 
ad libitum and maintained under a 12-hr light and 12-hr dark cycle. All 
animal experimental protocols were approved by the Institutional Animal 
Care and Usage Committee (IACUC) of Shiga University of Medical Science 
and were performed according to the guidelines of the IACUC of Shiga 
University of Medical Science. 
 
HAC-MSC preparation 
Human mesenchymal stem cells (MSCs) were immortalized by the 
combination of human telomerase reverse transcriptase (hTERT) and human 
papillomavirus 16 E6 and E7 (HPV16E6/E7) genes (Figure S1) (Okamoto et 
al., 2002). The MSCs were maintained in the Dulbecco's modified Eagle 
medium (Thermo Fisher Scientific, Waltham, MA, USA) with 10% fetal 
bovine serum (Thermo Fisher Scientific), 100 U/ml penicillin and 100 mg/ml 
streptomycin. Growth factor-expressing MSCs (HAC-MSCs) were generated 
by 21st human artificial chromosome (HAC) (Katoh et al., 2004) vector-
containing cDNAs for HGF, GDNF, IGF and GFP as per methods described 
previously (Watanabe et al, 2015). Control MSCs expressing only GFP by 
human artificial chromosome vector (GFP-MSCs) were prepared to compare 
with the effects of HAC-MSCs (Figure S1) (Watanabe et al., 2015). 
 
MNC preparation  
Total bone marrow cells were collected from tdTomato transgenic mice 
expressing red fluorescence, systemically. Mononuclear cells (MNCs) were 
isolated from the total bone marrow cells by using Ficoll-Paque Plus gradient 
separation (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). 
 
Bone marrow transplantation therapy with MNCs and HAC-MSCs for 
SOD1-tg mice 
HAC-MSCs and MNCs were prepared at 1 x 106 cells for each mouse as 
enough cell number for reconstitution of bone marrow. After irradiation of 
the recipient female SOD1-tg mice with 9 Gy, bone marrow transplantation 
(BMT) therapy with both MNCs and HAC-MSCs was performed for SOD1-tg 
mice at 8 weeks of age via the injection of tail vein. A week prior to the BMT 
(7 weeks old), an immunosuppressive agent FK506 (3 mg/kg/day, AdooQ 
Bioscience, Irvine, CA) was administered orally to mice until the mice showed 




Rota-Rod tests (Ugo Basile, Comerio-Varese, Italy) were demonstrated once 
per week for all treatment mice from 8 weeks of age until their physiological 
death (If the result of Rota-Rod tests is zero second, the condition of the mice 
is recognized as physiologically dead). Rota-Rod tests were performed at a 
range from 5rpm/min to a maximum of 50 rpm/min for 5 min (acceleration 
was 9 rpm/min2) as previously described (Terashima et al., 2014). Five times 
trial for each mouse with an interval of at least 3 min were performed and 
the averages of three medians were calculated for analysis. The number of 
survival mice was counted according to the definition of physiological death 
until all mice were recognized as such for the Kaplan-Meier survival curve. 
 
Histological analysis 
For histological analysis of tissues from the treated mice at 14-16- and 18-20-
week-old, transcardiac perfusion and fixation of 4% paraformaldehyde were 
performed. For immunostaining, sections of the spinal cord were prepared 
with a cryostat and incubated with a primary antibody (rabbit anti- 3-
tubulin [Cell Signaling Technology, MA, USA], rabbit anti-Iba-1 [Wako, 
Osaka, Japan], or rabbit anti-GFAP [Cell Signaling Technology, MA, USA]) 
at 4 °C overnight. Then, the sections were incubated with a secondary 
antibody (goat anti-rabbit Alexa 633 [Life Technologies, Carlsbad, CA, USA]) 
at room temperature for 4 hours and mounted with Vectashield without 
nuclear stain. Some sections of spinal cords were performed Nissl stain with 
NeuroTrace 435/455 (Thermo Fisher Scientific) for the analysis of 
degeneration of motor neuron. Other sections of the spinal cord and bone 
marrow from each mouse were mounted with the Vectashield mounting 
medium with DNA staining using 4´,6-diamidino-2-phenylindole (DAPI; 
Vector Laboratories, Burlingame, CA). These sections were observed under a 
confocal laser microscope (C1si; Nikon, Tokyo, Japan) with EZC1 3.90 
software (Nikon). For quantitative analysis, Nissl-positive staining and 
GFAP-positive immunostaining were converted to the black white image and 
the intensity was measured in over 10 scenes per each mouse by ImageJ 
software version 1.51 (National Institutes of Health, Bethesda, MD). The 
numbers of tdTomato-positive MNCs were counted and calculated per unit 
area, and determined by sampling from eight to 10 scenes for each individual. 
To analyze the muscle degeneration, anterior tibial muscle was isolated from 
the treated mice after transcardiac perfusion fixation by 4% 
paraformaldehyde. Frozen sections were prepared after the muscle was 
embedded in OCT compound (Sakura Finetek Japan, Tokyo, Japan), and 
were stained with hematoxylin-eosin. The area of muscle fibers was 
measured in over 10 scenes per each mouse by ImageJ software version 1.51 
(National Institutes of Health). 
 
Quantitative PCR of mRNA 
Total RNA in spinal cord from each mouse was extracted by using the RNeasy 
Kit (Qiagen, Valencia, CA) and digested with DNase I (Thermo Fisher 
Scientific). After reverse transcription using the oligo dT primer (Thermo 
Fisher Scientific), each mRNA expression level was analyzed by quantitative 
PCR using a LightCycler 480 (Roche Diagnostics, Manheim, Germany) with 
the SYBR green method. The following primers were used: human HGF, 
forward primer 5-GAAGGATCAGATCTGGTTTTAATGA-3 and reverse 
primer 5-TGCATCCATAATTAGGTAAATCAATC-3; human GDNF, forward 
primer 5-GTCTGCCTGGTGCTGCTC-3 and reverse primer 5-
GGATAATCCTCTGGCATATTTGAG-3; human IGF, forward primer 5-
TGTGGAGACAGGGGCTTTTA-3 and reverse primer 5-
ATCCACGATGCCTGTCTGA-3; tdTomato, forward primer 5-
GCCACTACCTGGTGGAGTTC-3 and reverse primer 5-
TGGTGTAGTCCTCGTTGTGG-3; GFP, forward primer 5-
TCATGGCCGACAAGCAGA-3 and reverse primer 5-
TCAGGTAGTGGTTGTCGGGCA-3; and -actin, forward primer 5-
CGTGCGTGACATCAAAGAGAA-3 and reverse primer 5-
TGGATGCCACAGGATTCCAT-3. Total RNA with DNase I digestion before 
reverse transcription was used as a negative control for each quantitative 
PCR and no amplification product originated from the HAC vectors was 
observed. The results were analyzed with LightCycler 480 software, version 
1.5 (Roche Diagnostics). All data ere normali ed to -actin expression. The 
results were compared among all groups. 
 
ELISA analysis for HGF, GDNF and IGF 
For in vitro analysis of protein expression of growth factors, MNCs, GFP-
MSCs and HAC-MSCs were prepared in 12 well-culture dishes at the cell 
density of 1 X 105 cells / well. After three days culture, the supernatant was 
collected from each cell culture and used for ELISA analysis of HGF, GDNF 
and IGF according to the manufactural protocol. 
For in vivo analysis of protein expression of growth factors, spinal cords were 
isolated from SOD1-tg mice in no treatment, MNCs, GFP-MSCs and HAC-
MSCs groups at middle stage (14-16 W) and at end stage (18-20 W) of disease 
status. The isolated spinal cords were homogenized into RIPA buffer (150mM 
Sodium Chloride, 2mM EDTA, 1% Sodium Deoxycholate, 0.1% Sodium 
Dodecyl Sulfate, 1.0% NP-40 substitute, 20mM Tris-HCl, pH7.4) with 
protease inhibitor cocktail (1tablet / 50ml buffer, Merck, Darmstadt, 
Germany). The supernatant was used for each ELISA analysis of HGF 
(Quantikine ELISA human HGF kit, R & D systems, Minneapolis, MN), 
GDNF (GDNF Human ELISA kit, Abcam, Cambridge, UK) and IGF 
(Quantikine ELISA human IGF-1 kit, R & D systems) according to the 
manufactural protocol. 
 
Cytokine assay in spinal cord tissues 
Spinal cord tissues were collected from SOD1-tg mice. After homogenization, 
the tissues were centrifuged at 15,000rpm. The supernatant of the spinal 
cord tissues was combined from over three mice in each group. The 32-
cytokine assay in the supernatant was outsourced to GeneticLab (Sapporo, 
Japan). The sample was used for running a multiplex assay, and the 
concentration of the 32 cytokines was measured with a Milliplex MAP kit 
HCYTMAG-70K-PX32 (Millipore, Burlington, MA) and a Luminex®200TM 
System (Luminex Corp, Austin, TX) using ELISA. The procedure was 
performed according to the assay protocols and guidelines provided by the 
manufacture. The cytokines included in the kit were as follows; G-CSF, 
Eotaxin, granulocyte macrophage-colony stimulating factor,  interferon- , IL-
1 , IL-1 , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12p40, IL-12p70, 
leukemia inhibitory factor, IL-13, LPS-induced CXC chemokine, IL-15, IL-17, 
interferon-  induced protein-10, keratinocyte-derived chemokines, monocyte 
chemoattractant protein-1, MIP-1 , MIP-1 , macrophage-colony stimulating 
factor, MIP-2, MIG, RANTES, tumor necrosis factor- , and VEGF. The 
results were calculated and analyzed by using the MasterPlex® software 
(Hitachi Solutions America, Ltd, Irvine, CA). 
 
Statistical analysis 
For multiple data sets, one- a  ANOVA and the Scheffe s test ere used. The 
log rank test was used for statistical analysis of the Kaplan-Meier curve. 
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